Although the majority of trials towards bsAbs focus on HER2-positive breast cancer, preclinical studies in TNBC showed promising immunomodulatory effects of BiTEs targeting TROP-2 resulting in reduced tumor growth [61]. The gene discussed is TACSTD2; the disease is breast carcinoma.